Talphera Inc (NAS:TLPH)

$ 0.70695 -0.01555 (-2.15%) Market Cap: 12.04 Mil Enterprise Value: 1.73 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 42/100

Q3 2024 Talphera Inc Earnings Call Transcript
Nov 13, 2024

$0.89 (-2.20%)

Earnings
Q2 2024 Talphera Inc Earnings Call Transcript
Aug 14, 2024

$0.86 (-5.49%)

Earnings
Q1 2024 Talphera Inc Earnings Call Transcript
May 14, 2024

$1.02 (-0.98%)

Earnings
Q4 2023 Talphera Inc Earnings Call Transcript
Mar 06, 2024

$1.27 (+1.60%)

Earnings
AcelRx Pharmaceuticals Inc To Host KOL Event Transcript
Dec 06, 2023
Q3 2023 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2023

$0.5301 (+1.81%)

Earnings
Q2 2023 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2023

$0.898 (-5.46%)

Earnings
Q1 2023 AcelRx Pharmaceuticals Inc Earnings Call Transcript
May 10, 2023

$0.7125 (+3.85%)

Earnings
Q4 2022 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Mar 30, 2023

$0.7 (-2.78%)

Earnings
Q3 2022 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2022

$2.43 (+17.96%)

Earnings
Q2 2022 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2022

$6.25 (+33.02%)

Earnings
Q1 2022 AcelRx Pharmaceuticals Inc Earnings Call Transcript
May 16, 2022

$4.19 (-0.14%)

Earnings
AcelRx Pharmaceuticals Inc To Discuss its Recently Acquired Late-stage Product Candidate, Niyad™ Transcript
May 04, 2022
Q4 2021 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Mar 10, 2022

$8.64 (-1.66%)

Earnings
Q3 2021 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Nov 15, 2021

$14.92 (-6.08%)

Earnings
Q2 2021 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Aug 16, 2021

$22.4 (-4.27%)

Earnings
Q1 2021 AcelRx Pharmaceuticals Inc Earnings Call Transcript
May 17, 2021

$23.6 (+1.72%)

Earnings
Q4 2020 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Mar 15, 2021

$43.6 (-1.80%)

Earnings
AcelRx Pharmaceuticals Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 10, 2020
Q3 2020 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020

$37.4 (+2.19%)

Earnings
AcelRx Pharmaceuticals, Inc. - Special Call Transcript
Oct 07, 2020
Q2 2020 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2020

$27.6 (+4.55%)

Earnings
Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call Transcript
May 11, 2020

$33.8 (+9.03%)

Earnings
Q4 2019 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Mar 16, 2020

$16.8 (-18.46%)

Earnings
AcelRx Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 13, 2019
Q3 2019 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Nov 06, 2019

$38.2 (-5.91%)

Earnings
Q2 2019 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2019

$48.2 (-0.41%)

Earnings
Q1 2019 AcelRx Pharmaceuticals Inc Earnings Call Transcript
May 08, 2019

$70.2 (-1.40%)

Earnings
Q4 2018 AcelRx Pharmaceuticals Inc Earnings Call Transcript
Mar 07, 2019

$75.2 (+4.16%)

Earnings

Q2 2024 Talphera Inc Earnings Call Transcript

Aug 14, 2024 / 08:30PM GMT

Release Date Price: $0.86 (-5.49%)

Transcript 8-K10-Q

Operator

Welcome to Talphera's second-quarter 2024 financial results conference call. This call is being webcasted live via the Events page of the Investors section of Talphera's website at www.talphera.com. This call is the property of Talphera, and any recording, reproduction or transmission of this call without the expressed written consent of Talphera is prohibited

As a reminder, this webcast is being recorded. You may listen to a replay of this webcast by going to the Investors section of Talphera's website.

I would now like to turn the call over to Raffi Asadorian, Talphera's Chief Financial Officer.

Raffi Asadorian

Talphera Inc - Chief Financial Officer

Thank you for joining us on the call today. This afternoon, we announced our second-quarter 2024 financial results and associated business updates in a press release. This press release can be found within the Investors section of our website. With me today are Vince Angotti, our Chief Executive Officer; and Dr. Pam Palmer,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.